Eli Lilly signals beyond the news: 59+ signals from 6 sources
The latest Eli Lilly signal on this page is from Sep 29, 2026 (Patents): "Eli Lilly and Company's patent output is steady: 89 grants in the past year, 7 in the past 30 days." The busiest sources: Glassdoor (15+), LinkedIn (15+) and Patents (9).
- Signals
- 59+
- Sources
- 6
- Last 90 days
- 53
- Latest
- Sep 29, 2026
Other signals · latest 10
Latest Eli Lilly signals by source
59+ signals for Eli Lilly across 6 sources.
Patents · Patent pace
Eli Lilly and Company's patent output is steady: 89 grants in the past year, 7 in the past 30 days.
Over the past year Eli Lilly and Company received 89 US patent grants, concentrated in health tech / medical informatics and computer vision; the recent pace (23 in 90 days) is steady versus its trailing baseline.
- Grants, 12 months
- 89
- Grants, 90 days
- 23
- Grants, 30 days
- 7
- USPTO assignee
- ELI LILLY AND COMPANY
Podcasts · Data investment
TFTC: A Bitcoin Podcast discusses Eli Lilly: data investment
"They have ToonLab, which is a way for them brilliantly to collect other data, combine it with their data on an anonymous basis. But it helps them learn from their data while giving biotech companies the ability of testing their data on Eli Lilly's data."
- Podcast
- TFTC: A Bitcoin Podcast
- Episode
- #795: Tokenization Unlocks $900 Trillion in Wealth with Jordi Visser
- Speaker
- Jordi Visser
- Speaker role
- Third party
Reddit · Legal action
A commenter alleges that the FDA discovered fraud in historical clinical trials for Eli Lilly's antidepressant Prozac, where doctor investigators supposedly concealed serious adverse events like...
Post: "Eli Lilly Horror"
- Subreddit
- r/clinicalresearch
- Upvotes
- 54
- Comments
- 38
- Sentiment
- Negative
Reddit · Customer feedback
Eli Lilly's FSP is described as the 'least liked', with a reputation for overworking its employees.
Post: "Sponsor/FSP Rankings"
- Subreddit
- r/clinicalresearch
- Upvotes
- 24
- Comments
- 46
- Sentiment
- Negative
Patents · Patent grant
Eli Lilly was granted a patent for multi-receptor incretin medicines.
In September 2026 Eli Lilly patented longer-acting treatments for diabetes, obesity, fatty liver disease, and related metabolic conditions.
- Patent title
- Incretin analogs and uses thereof
- Grant date
- Sep 22, 2026
- Inventors
- Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
Podcasts · Industry prediction
The Pomp Podcast discusses Eli Lilly: industry prediction
"So where Eli Lilly figured this out is like, that means all of this dormant IP that exists, all these biotech companies, they've got something that people invested in. Let's go through all of their stuff and see which public information on their research is worth something. And let's finish it."
- Podcast
- The Pomp Podcast
- Episode
- Bitcoin Is About To Go Parabolic Because Of AI Agents | Jordi Visser
- Speaker
- Jordi Visser
- Speaker role
- Third party
Glassdoor · Cross functional collaboration issues
Communication silos and organizational changes impact employee experience
One associate director mentioned communication silos and organizational changes, while another review noted that business weighs more than culture.
- Overall rating
- 4.0 of 5
- CEO approval
- 89%
- Reviews read
- 10
- Review window
- Sep 2, 2026 to Sep 9, 2026
Glassdoor · Consistent leadership complaints
Leadership decisions and communication impact employees negatively across multiple reviews
Reviews cite non-technical leadership, process teams negatively affecting work-life balance, and a principal automation engineer detailing disrespectful policy changes from higher leadership.
- Overall rating
- 4.0 of 5
- CEO approval
- 89%
- Reviews read
- 10
- Review window
- Sep 2, 2026 to Sep 9, 2026
X (Twitter)
New one-year data shows durable improvements in psoriasis, psoriatic arthritis, and obesity.
New one-year data showed durable improvements in psoriasis, psoriatic arthritis and obesity: https://t.co/WZCbewxrg7 https://t.co/HZZSMuiIHP
- Account
- @EliLillyandCo
- Views
- 6,305
- Likes
- 21
- Reposts
- 5
LinkedIn
Smith Integrative Oncology warns about black market Retatrutide and patient safety risks.
Obesity management medicines are all over the headlines - and some bad actors are exploiting that attention on the black market. Retatrutide is an investigational molecule still in clinical trials and is not approved for sale to consumers anywhere in the world. Any product marketed as retatrutide or “reta” poses...
- Likes
- 283
- Comments
- 5
- Tags
- Pharmaceuticals, Compliance, Healthcare Technology
- Initiatives
- patient education on drug safety
Showing 10 of 59+ signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Eli Lilly with the Signal API
One POST /v1/companies/enrich call with lilly.com returns Eli Lilly signals from 14 more signal types (reddit-company, podcast-company, glassdoor-company and more), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{
"domain": "lilly.com",
"signal_types": ["reddit-company","podcast-company","glassdoor-company",
"product-reviews","linkedin-post-company","twitter-company-posts",
"youtube-company","website-intelligence","patents-company",
"federal-contract-award","conference-speaker","hackernews",
"producthunt-launch","seo-traffic"],
"limit": 20
}'Same industry
Other signals at related companies
Questions about Eli Lilly other signals
What signals does Autobound track for Eli Lilly besides news and filings?
What are people saying about Eli Lilly online?
What do employees say about working at Eli Lilly?
Has Eli Lilly been granted patents recently?
Source. Reddit, podcasts, Glassdoor, product reviews, LinkedIn, X, YouTube, company websites, patents, federal contracts, conference talks, Hacker News, Product Hunt, web traffic and employee growth, from the Signal API.
Method. The latest 15 signals per source from the last 12 months. Posts that do not name the company, replies, repeats and unreadable rows are removed. Traffic and headcount keep their newest measure.
Data as of .